Inhibikase Therapeutics (IKT) Common Equity (2020 - 2025)
Historic Common Equity for Inhibikase Therapeutics (IKT) over the last 6 years, with Q3 2025 value amounting to $72.9 million.
- Inhibikase Therapeutics' Common Equity rose 1383907.55% to $72.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.9 million, marking a year-over-year increase of 1383907.55%. This contributed to the annual value of $94.9 million for FY2024, which is 76415.52% up from last year.
- Inhibikase Therapeutics' Common Equity amounted to $72.9 million in Q3 2025, which was up 1383907.55% from $80.1 million recorded in Q2 2025.
- Inhibikase Therapeutics' 5-year Common Equity high stood at $94.9 million for Q4 2024, and its period low was -$530591.0 during Q3 2024.
- Over the past 5 years, Inhibikase Therapeutics' median Common Equity value was $25.3 million (recorded in 2023), while the average stood at $34.8 million.
- Per our database at Business Quant, Inhibikase Therapeutics' Common Equity plummeted by 10353.31% in 2024 and then skyrocketed by 1383907.55% in 2025.
- Inhibikase Therapeutics' Common Equity (Quarter) stood at $38.4 million in 2021, then crashed by 45.24% to $21.0 million in 2022, then plummeted by 47.81% to $11.0 million in 2023, then surged by 764.16% to $94.9 million in 2024, then decreased by 23.16% to $72.9 million in 2025.
- Its Common Equity stands at $72.9 million for Q3 2025, versus $80.1 million for Q2 2025 and $85.7 million for Q1 2025.